PMID- 29167002
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20181202
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 20
IP  - 11
DP  - 2017 Nov 20
TI  - [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell 
      Lung Cancer after Failure to Multiple-lines Treatments].
PG  - 737-740
LID - 10.3779/j.issn.1009-3419.2017.11.03 [doi]
AB  - BACKGROUND: The development of new treatments beyond first-line in metastatic 
      non-small cell lung cancer (NSCLC) contributed to the increase in overall 
      survival. Metronomic chemotherapy involves several mechanisms of anti-tumor with 
      less toxicity. Oral vinorelbine has paved the way for innovative treatment 
      strategies through metronomic regimens. Therefore, this study assessed the 
      efficacy and safety of metronomic oral vinorelbinen in advanced NSCLC after 
      failure to multiple-lines treatments. METHODS: Our retrospective study enrolled 
      26 patients who received metronomic oral vinorelbinen. Survival factors were 
      evaluated by univariate regression analysis. RESULTS: The median follow-up time 
      was 4 months (range 2-12). The median number of treatment cycles was 2 (range 
      1-8). No patient achieved complete remission, 2 cases (8%) partial remission, 11 
      cases (42%) stable disease, 13 cases (50%) progression disease. Overall response 
      rate was 8% and disease control rate was 50%. The median progression-free 
      survival (PFS) was 2 months. In univariate analysis, patients with performance 
      status (PS)=1 had a statistically significantly longer PFS than patients with 
      PS=2. Gender, age, smoking status and histology were not prognostic factors 
      according to PFS. Treatment was well tolerated with rare serious toxicity. No 
      grade 4 adverse events (AEs) or occurrences of intolerable toxicity were 
      observed. There was no treatment-related death and none of the study patients 
      required hospitalization for treatment-related adverse events. CONCLUSIONS: 
      Metronomic oral vinorelbinen is effective in advanced NSCLC after the failure of 
      multiple lines treatments with an acceptable AE profile, especially in patients 
      with high PS.
.
FAU - Yao, Shuyang
AU  - Yao S
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing 100053, China.
FAU - Gu, Yanfei
AU  - Gu Y
AD  - Beijing United Family Healthcare Hospital, Beijing 100015, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing 100053, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
MH  - Administration, Metronomic
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Phytogenic/administration & dosage/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Vinblastine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Vinorelbine
PMC - PMC5973282
OTO - NOTNLM
OT  - Efficacy
OT  - Lung neoplasms
OT  - Metronomic chemotherapy
OT  - Safety
OT  - Vinorelbinen
EDAT- 2017/11/24 06:00
MHDA- 2018/03/13 06:00
PMCR- 2017/11/20
CRDT- 2017/11/24 06:00
PHST- 2017/11/24 06:00 [entrez]
PHST- 2017/11/24 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
PHST- 2017/11/20 00:00 [pmc-release]
AID - zgfazz-20-11-737 [pii]
AID - 10.3779/j.issn.1009-3419.2017.11.03 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2017 Nov 20;20(11):737-740. doi: 
      10.3779/j.issn.1009-3419.2017.11.03.